Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Zucca
E
E
Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
Dreyling
M
M
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D015415:Biomarkers / Q000378:metabolism; D001706:Biopsy; D001944:Breath Tests; D004724:Endoscopy; D005060:Europe / Q000453:epidemiology; D005243:Feces / Q000737:chemistry; D005500:Follow-Up Studies; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy; D006801:Humans; D015994:Incidence; D007770:L-Lactate Dehydrogenase / Q000032:analysis; D016393:Lymphoma, B-Cell / Q000737:chemistry / Q000473:pathology* / Q000601:surgery; D018442:Lymphoma, B-Cell, Marginal Zone / Q000175:diagnosis* / Q000628:therapy*; D009367:Neoplasm Staging; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D055502:Secondary Prevention; D013274:Stomach Neoplasms / Q000175:diagnosis* / Q000382:microbiology / Q000628:therapy*; D014508:Urea / Q000032:analysis; D001613:beta 2-Microglobulin / Q000032:analysis
D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D015415:Biomarkers; D001613:beta 2-Microglobulin; D014508:Urea; D007770:L-Lactate Dehydrogenase